medigraphic.com

2000, Number 3

<< Back Next >>

Cir Cir 2000; 68 (3)

Malignant melanoma. Study of 51 cases

Montiel-Jarquin Á, Herrera-Calderón F, Galicia-Ramos JM, Carrillo-Pérez E

Language: Spanish
References: 37
Page: 114-119
PDF size: 220.99 Kb.


ABSTRACT

Cancer was already known in ancient Greece and its study had progressed significantly. It was Hippocrates, certainly the greatest physician of this period, who named this strange disease. From this historical content arises the term malignant melanoma (MM), referring to a condition of uncertain biology and unpredictable development, ranging from spontaneous regression to rapid progression and death. Objectives: To review the files of the Departamento de Patología of the Hospital de Especialidades del Centro Médico Nacional M. Ávila Camacho in Mexico City for the years 1990-1994 to gather statistics on MM in order to provide the basis for future analytical studies of the disease. Results: We found 51 cases of MM. In our environment, MM is most frequent in the fifth and sixth decades of life, is equally represented in both sexes and most frequently occurs in the lower extremities in areas not exposed to the sun. The most important prognosis factors were the Clark and Breslow levels and the presence or absence of metastases. In conclusion it is concluded that the MM is not a rare disease in our environment, that the epidemiological variables and the clinical and histopathologic parameters of this study agree with those reported in large Caucasian and North American studies, and that long-term horizontal studies are needed to be able to evaluate other relevant parameters, such as the therapeutic value of routine treatments, and survival rates. The present study also provides the basis for future analytical and long-term research.


REFERENCES

  1. Lickiss JN et al. Palliative care and melanoma. The care of the patient with progressive disease. World J Surg 1992; 16: 286.

  2. WHO. Expert Committee: Cancer pain relief and palliative care. Technical Report Series. Geneva, Switzerland: WHO; 1990.

  3. Social Development Committee: Inquiry into options for dying with dignity Second and final report. Parliament of Victoria, Melbourne, Australia 1987.

  4. McCarthy W, Shaw H. Malignant melanoma, introduction. World J Surg 1992; 16: 155-6.

  5. Balch CH, Karakousis C et al. Management of cutaneous melanoma in the United States. Surg Gynecol Obstet 1984; 58: 311-18.

  6. Rivers J. The detection and management of dysplastic nevi and early melanoma. Wold J Surg 1992; 16: 166-172.

  7. Boring C, Squires T, Tong T. Cancer stat 1991; CA 41: 19.

  8. Koh HK et al. Systematic underraporting of cutaneous malignant melanoma in Massachusetts. J Am Acad Dermatol 1991; 24: 545.

  9. Crowley N. Malignant melanoma in black Americans. A trend toward improved survival. Arch Surg 1991; 126: 1359-65.

  10. Rodríguez S, Labastida S, Huerta J, Zepeda G, Herrera Calderón F. Aspectos epidemiológicos del melanoma en México. Cir Cir 1994; 61(2): 64-7.

  11. Lenish W. Survival from preinvasive and invasive malignant melanoma in Western Australia. Cancer 1983; 52: 586-5.

  12. Crotty K et al. Malignant melanoma in childhood: a clinocopathologic study of 13 cases and comparison with Spitz nevi. World J Surg 1982; 16: 179-85.

  13. Beile V, VonKleist S et al. Cytokine levels in whole blood cell cultures as parameters of the cellular immunologic activity in patients with malignant melanoma and basal cell carcinoma. Cancer 1993; 71(1): 231-6.

  14. Ringbor V, Lagerloff B et al. Cutaneous malignant melanoma of the head and neck. Cancer 1993; 71(3): 751-8.

  15. O’Brien CH, Gianoutsos M, Morgan M. Neck dissection for cutaneous malignant melanoma. World J Surg 1992; 16: 222-26.

  16. Lee S, Shinizi K. Malignant melanoma in mucosas of the head and neck. Laryngoscope 1994: 104.

  17. Guzzo M, Grandi C, Lietra I, Podegreen S et al. Melanoma de mucosas del cuello y cabeza: 48 casos tratados en el Instituto Nazionale Tumori de Milan. Eur J Sur Oncol 1993; 19(4): 316-9.

  18. Morison W, Baughman R, Day R, Forbes P, Hoengsmann H, Krueger G, Lebwohl M et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998; 134(5): 595-8.

  19. Elwood M. Melanoma and sun exposure. Contrats between intermittent and chronic exposure. World J Surg 1992; 16: 157-65.

  20. Shaw H, Rivers J et al. Cutaneous melanomas exhibiting unusual biologic behavior. World J Surg 1992; 16: 196-202.

  21. Kepper R. Hereditary melanoma and the search for the melanoma gene. World J Surg 1992; 16: 246-50.

  22. De Vita V, Hellman S, Rosenberg S. Cáncer. Principios y práctica de oncología. 1ra. ed. Vol. II Editorial Salvat 1984: 1036-65.

  23. Madajewiz S, Karakousis C et al. Malignant melanoma brain metastases. Cancer 1984; 53: 2550-52.

  24. Lienard D et al. In transit metastases of malignant melanoma treated by high dose rTNF alfa in combination wiht interferon gamma and melphalan in isolation perfusion. World J Surg 1992; 16: 234-40.

  25. McCarthy W, Shaw H et al. Elective lymph node dissection for melanoma: two perspectives. World J Surg 1992; 16: 203-B.

  26. Cochran A, Duan-Ren W, Morton D. Management of the regional lymph nodes in patients with cutaneous malignant melanoma. World J Surg 1992; 16: 214-221

  27. Brozeno S. Malignant melanoma management guidelines. Geriatrics 1990; 45: 55.

  28. Clark W, From L, Bernardino E, Mihm M. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29: 705-26.

  29. Breslow A. Thickness, cross-sectional areas, and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902-8.

  30. Balch C, Murad T, Soong S et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark’s and Breslow’s staging methods. Ann Sur 1978; 188: 732-42.

  31. Breslow A. Tumor thickness, level of invasion and node disection in Stage I cutaneous melanoma. Ann Surg 1975; 182: 572-5.

  32. Kelly J, Sagebiel R, Clyman S, Blois M. Thin level IV malignant melanoma: a subset in which level is the major prognostic indicator. Ann Surg 1985; 202: 98-103.

  33. Scott R, McKay A. Elective lymph node dissection in the management of malignant melanoma. Br J Sur 1993; 80: 284-88.

  34. Secretaría de Salud. Compendio del registro histopatológico de neoplasias malignas 1993, 2ª ed. México: Secretaría de Salud 1995.

  35. Alfeiran RA, Escobar AG, Barreda BF, Herrera GA et al. Epidemiología del melanoma de piel en México. Rev Inst Nal Cancerol (Mex) 1998; 14(4): 168-174.

  36. Magaña-García M. Melanoma maligno. Aspectos clínicos en la población mexicana. Dermatología 1991; 35: 313.

  37. Balch CM, Soong SJ, Milton GW, Shaw HM, McGovern VJ, McCarthy WH. Changing trends in cutaneous melanoma over a quarter century in Alabama, USA, and now South Weles, Australia. Cancer 1983; 52: 1748.




2020     |     www.medigraphic.com